Chad Jennings helps FDA-regulated companies and financial institutions navigate complex transactions, particularly relating to life sciences and biotechnology.

Mr. Jennings approaches each matter with a data-focused perspective and leverages a comprehensive understanding of his clients’ business objectives to assess risk associated with US Food and Drug Administration (FDA) regulation within the transactional context. He advises clients across the drug, biologics, medical device, food, and dietary supplement sectors in:

  • Capital markets offerings
  • Public and private financings
  • Mergers and acquisitions
  • Strategic transactions
  • Loan transactions and debt facilities
  • Public company representation matters

He draws on a breadth of regulatory advisory experience to advise clients on risks associated with pre-commercial product development and clinical and pre-clinical testing, product promotion and labeling, and product manufacturing and quality matters.

Mr. Jennings served as a judicial intern for Judge Norman K. Moon at the US District Court for the Western District of Virginia. Before law school, Mr. Jennings performed consulting work for a liberal arts college developing undergraduate business curriculum and research materials relating to finance and international investment.

A recognized thought leader, he participates with the Food and Drug Law Institute, including speaking at industry events.

Mr. Jennings’ recent experience includes representing:

Biopharmaceuticals and Biologics

  • The underwriters on Alpine Immune Sciences’ US$100 million IPO
  • Arcutis Biotherapeutics, an early commercial-stage biopharmaceutical company focused on immuno-dermatology, on its public offering
  • The underwriters on Chinook Therapeutics’ US$105 million public offering
  • The initial purchasers in Cytokinetics’ US$540 million convertible senior notes offering
  • Geron, a late-stage clinical biopharmaceutical company, on its US$198 million upsized initial public offering (IPO)
  • The initial purchasers in Halozyme Therapeutics’ upsized private offering of US$625 million of convertible senior notes
  • Hercules Capital on:
    • A financing agreement for Kura Oncology, a clinical-stage biopharmaceutical company
    • Tricida’s US$125 million debt facility
  • HilleVax on its upsized IPO
  • The lenders to support Kindeva Drug Delivery’s combination with Meridian Medical Technologies to create a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products
  • Ligand Pharmaceuticals on completing the spln-off off its OmniAb antibody discovery business and its subsequent business combination with Avista Public Acquisition Corp. II, resulting in OmniAb becoming an independent publicly traded company
  • Mineralys Therapeutics, a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, on its upsized IPO
  • The underwriters in Mirum Pharmaceuticals’ public offering
  • Rhythm Pharmaceuticals in a revenue interest financing agreement with HealthCare Royalty Partners for up to US$100 million
  • The underwriters in a US$600 million public offering for Vaxcyte, a clinical-stage vaccine innovation company engineering high-fidelity vaccines

Medical Device and Medical Technology

  • AcuFocus, a privately held ophthalmic medical device company, on its acquisition by a Bausch + Lomb affiliate
  • Affera in its sale to Medtronic
  • Alphatec Holdings, a medical technology company focused on surgical treatment for spinal disorders, on a US$150 million nondilutive term loan agreement with life sciences firm Braidwell
  • The direct lender to support AWA Investors’ acquisition of Burke Porter Group, a global provider of automated diagnostic, testing, and production solutions, from CEL Global Investment Fund
  • ICU Medical in its US$1 billion acquisition of Pfizer’s Hospira Infusion Systems business
  • MedAlliance on its US$1.135 billion acquisition by Cordis
  • SLR Capital Partners on US$300 million debt facilities for Outset Medical, a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis


  • Astorg and portfolio company Solina, a leading Euripean producer of savory ingredient solutions for the food industry, on acquiring Saratoga Food Specialties in a carve-out transaction from Smithfield Foods

Bar Qualification

  • District of Columbia
  • Massachusetts


  • JD, University of Virginia School of Law, 2014
    Order of the Coif
  • MA, University of Virginia, 2007
  • BA, Virginia Polytechnic Institute and State Univ., 2005
    summa cum laude